Adage Capital Partners
VRNA

Adage Capital Partners’s Verona Pharma VRNA Stock Holding History

Adage Capital Partners’s Portfolio VRNA Stock Details VRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-816,715
Closed -$77.2M – 983
2025
Q2 		$77.2M Sell
816,715
-814,285
-50% -$60.3M 0.13% 158
2025
Q1 		$104M Buy
1,631,000
+1,292,575
+382% +$77.3M 0.19% 104
2024
Q4 		$15.7M Buy
+338,425
New +$12.7M 0.03% 495
2024
Q3 		– Sell
-175,000
Closed -$2.53M – 944
2024
Q2 		$2.53M Hold
175,000
– – ﹤0.01% 768
2024
Q1 		$2.82M Sell
175,000
-476,931
-73% -$8.25M 0.01% 754
2023
Q4 		$13M Buy
651,931
+225,000
+53% +$3.32M 0.03% 539
2023
Q3 		$6.96M Buy
426,931
+208,100
+95% +$4.01M 0.02% 623
2023
Q2 		$4.63M Sell
218,831
-18,100
-8% -$386K 0.01% 678
2023
Q1 		$4.76M Buy
236,931
+155,000
+189% +$3.35M 0.01% 713
2022
Q4 		$2.14M Sell
81,931
-349,885
-81% -$4.66M 0.01% 814
2022
Q3 		$4.41M Buy
+431,816
New +$3.64M 0.01% 795

Other funds holding VRNA

PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Adage Capital Partners's VRNA Position: Q3 2025 in Review

Adage Capital Partners sold out of Verona Pharma (VRNA) in Q3 2025, closing a stake of 816,715 shares — an estimated $77.2M sold.

Adage Capital Partners first reported a position in VRNA in Q3 2022 and held it in 11 quarters. The position peaked at $104M in Q1 2025. 243 funds tracked by Wall St. Rank hold VRNA as of Q3 2025.

  • Adage Capital Partners reported no remaining Verona Pharma position as of Q3 2025 after selling out during the quarter.
  • Adage Capital Partners sold 816,715 Verona Pharma shares in Q3 2025, an estimated $77.2M.
  • Adage Capital Partners first reported a position in Verona Pharma in Q3 2022 and held it in 11 quarters.
  • Adage Capital Partners's Verona Pharma position peaked at $104M in Q1 2025.
  • 243 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2025.

Based on Adage Capital Partners's 13F filing for Q3 2025, filed 14 Nov 2025.